Research programme: mRNA therapeutics - Roquefort Therapeutics
Alternative Names: MDK mRNALatest Information Update: 10 May 2024
At a glance
- Originator Roquefort Therapeutics
- Class Antineoplastics; RNA
- Mechanism of Action MDK protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 29 Apr 2024 mRNA therapeutics is available for licensing as of 29 Apr 2024. https://www.roquefortplc.com/partnering (Roquefort Therapeutics website, April 2024)
- 06 Feb 2024 Preclinical trials in Solid tumours in United Kingdom (Parenteral) before February 2024
- 13 Jun 2023 Roquefort Therapeutics files patents to protect the MDK mRNA programme